Breast Cancer Clinical Trial
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Summary
The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been terminated.
This study will also provide another mechanism for reporting adverse events related to study drug safety.
Eligibility Criteria
Inclusion Criteria:
Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of ruxolitinib that has completed or been terminated.
Currently tolerating treatment in the parent protocol.
Currently benefiting from the treatment with ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone, as determined by the investigator.
Have at least stable disease, as determined by the investigator.
Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.
Exclusion Criteria:
Has been permanently discontinued from study treatment in the parent study for any reason.
Able to access ruxolitinib and/or background cancer therapy outside of the clinical study.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 6 Locations for this study
Santa Monica California, 90404, United States
Louisville Kentucky, 40202, United States
Clifton Park New York, 12065, United States
Nashville Tennessee, 37203, United States
Houston Texas, 77005, United States
Houston Texas, 77030, United States
How clear is this clinincal trial information?